Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Postmenopausal women show a more atherogenic lipid profile and elevated cardiovascular risk compared to premenopausal women. The aim of this study was to investigate the efficacy and safety of high-dose atorvastatin on the improvement of the blood lipid profile of postmenopausal women in Korea. Methods: This study is a prospective, open-label, single-arm clinical trial that was conducted in 3 teaching hospitals. Postmenopausal women with a moderate-to-high cardiovascular risk, according to guidelines from the Korean Society of Lipid & Atherosclerosis, were enrolled. Participants were administered 20 mg of atorvastatin daily for the first 8 weeks, and if the targeted low-density lipoprotein cholesterol (LDL-C) level was not achieved, the dose was increased to 40 mg for the second 8 weeks. The primary endpoint was percentage change of LDL-C from baseline after 16 weeks of drug administration. Results: Forty-four women were enrolled, 28 of whom (75.6%) had diabetes mellitus. By the end of treatment period (16 weeks) all patients had achieved LDL-C target levels, with 33 (94.2%) of the participants achieving it after only 8 weeks of administration. After 16 weeks, LDL-C decreased by 45.8±16.7% (p<0.001) from the baseline, and total cholesterol (33.2±10.9%; p<0.001), triglyceride (24.2±37.5%; p=0.001), and apolipoprotein B (34.9±15.6%; p<0.001) also significantly decreased. Blood glucose and liver enzyme levels slightly increased, but none of the participants developed serious adverse events that would cause them to prematurely withdraw from the clinical trial. Conclusion: 20 and 40 mg atorvastatin was effective and safe for treating dyslipidemia in postmenopausal Korean women with moderate-to-high cardiovascular risk.
Abstract
Objective: Postmenopausal women show a more atherogenic lipid profile and elevated cardiovascular risk compared to premenopausal women. The aim of this study was to investigate the efficacy and safety of high-dose atorvastatin on the improvement of the blood lipid profile of postmenopausal women in Korea. Methods: This study is a prospective, open-label, single-arm clinical trial that was conducted in 3 teaching hospitals. Postmenopausal women with a moderate-to-high cardiovascular risk, according to guidelines from the Korean Society of Lipid & Atherosclerosis, were enrolled. Participants were administered 20 mg of atorvastatin daily for the first 8 weeks, and if the targeted low-density lipoprotein cholesterol (LDL-C) level was not achieved, the dose was increased to 40 mg for the second 8 weeks. The primary endpoint was percentage change of LDL-C from baseline after 16 weeks of drug administration. Results: Forty-four women were enrolled, 28 of whom (75.6%) had diabetes mellitus. By the end of treatment period (16 weeks) all patients had achieved LDL-C target levels, with 33 (94.2%) of the participants achieving it after only 8 weeks of administration. After 16 weeks, LDL-C decreased by 45.8±16.7% (p<0.001) from the baseline, and total cholesterol (33.2±10.9%; p<0.001), triglyceride (24.2±37.5%; p=0.001), and apolipoprotein B (34.9±15.6%; p<0.001) also significantly decreased. Blood glucose and liver enzyme levels slightly increased, but none of the participants developed serious adverse events that would cause them to prematurely withdraw from the clinical trial. Conclusion: 20 and 40 mg atorvastatin was effective and safe for treating dyslipidemia in postmenopausal Korean women with moderate-to-high cardiovascular risk.
참고문헌 (35)
- Baigent C, "Efficacy and safety of cholesterol-lowering treatment : prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins", Lancet, 366, pp.1267~1278 (2005)
- Poli A, "Atorvastatin : pharmacological characteristics and lipid-lowering effects", Drugs, 67(Suppl 1), pp.3~15 (2007)
- Black DM, "An overview of the clinical safety profile of atorvastatin(lipitor), a new HMG-CoA reductase inhibitor", Arch Intern Med, 158, pp.577~584 (1998)
- Jones P, "Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia(the CURVES study)", Am J Cardiol, 81, pp.582~587 (1998)
- Amarenco P, "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355, pp.549~559 (2006)
- Cannon CP, "Intensive versus moderate lipid lowering with statins after acute coronary syndromes", N Engl J Med, 350, pp.1495~1504 (2004)
- Colhoun HM, "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS) : multicentre randomised placebo-controlled trial", Lancet, 364, pp.685~696 (2004)
- Sever PS, "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm(ASCOT-LLA) : a multicentre randomised controlled trial", Lancet, 361, pp.1149~1158 (2003)
- Law MR, "Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke : systematic review and meta-analysis", BMJ, 326, pp.1423~ (2003)
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63[DOI]
- Kobayashi T, "Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3", 2, E3, 3, pp.J Clin Pharmacol, 2001[DOI]
- 공성혜, "Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus", Diabetes and Metabolism Journal, 41(1), pp.23~30 (2017), 대한당뇨병학회[DOI]
- Kwon JE, "Cholesterol lowering effects of low-dose statins in Korean patients", J Lipid Atheroscler, 3, pp.21~28 (2014)
- Matsuzawa Y, "Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51, 321 Japanese hypercholesterolemic patients", Circ J, 67, pp.287~294 (2003)
- Wu CC, "Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study", J Formos Med Assoc, 101, pp.478~487 (2002)
- Arai H, "Comment on the new guidelines in USA by the JAS guidelines committee", J Atheroscler Thromb, 21, pp.79~81 (2014)
- McPherson R, "Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease", Can J Cardiol, 22, pp.913~927 (2006)
- Matthews KA, "Menopause and risk factors for coronary heart disease", N Engl J Med, 321, pp.641~646 (1989)
- Wu ZY, "Relationship of menopausal status and sex hormones to serum lipids and blood pressure", Int J Epidemiol, 19, pp.297~302 (1990)
- Bush TL, "The epidemiology of cardiovascular disease in postmenopausal women", Ann N Y Acad Sci, 592, pp.263~271 (1990)
- Kannel WB, "Metabolic risk factors for coronary heart disease in women : perspective from the Framingham Study", Am Heart J, 114, pp.413~419 (1987)
- Davidson MH, "Management of hypercholesterolaemia in postmenopausal women", Drugs Aging, 19, pp.169~178 (2002)
- Son JI, "Treatment guidelines for dyslipidemia : summary of the expanded second version", J Lipid Atheroscler, 1, pp.45~59 (2012)
- Koh JH, "Efficacy and safety of atorvastatin in patients with hypercholesterolemia", Korean Circ J, 29, pp.928~936 (1999)
- 박종선, "Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia", The Korean Journal of Internal Medicine, 25(1), pp.27~35 (2010), 대한내과학회
- Seon Young PARK, "Comparative Drug Evaluation of Atorvastatin versus Rosuvastatin in Pharmacotherapy of Korean Patients with Dyslipidemia", Biomolecules & Therapeutics, 16(1), pp.54~60 (2008), 한국응용약물학회
- Semenkovich CF, "Williams textbook of endocrinology", pp.1660~1700 (2016), Saunders
- 전상성, "고지혈증 환자에서 Atorvastatin(Lipitor)의 혈청지질 강하 효과", Korean Journal of Family Medicine, 25(1), pp.46~51 (2004), 대한가정의학회
- Ridker PM, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359, pp.2195~2207 (2008)
- Ridker PM, "Cardiovascular benefits and diabetes risks of statin therapy in primary prevention : an analysis from the JUPITER trial", Lancet, 380, pp.565~571 (2012)
- Sattar N, "Statins and risk of incident diabetes : a collaborative meta-analysis of randomised statin trials", Lancet, 375, pp.735~742 (2010)
- Stratton IM, "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes(UKPDS 35) : prospective observational study", BMJ, 321, pp.405~412 (2000)
- Catapano AL, "2016 ESC", EAS guidelines for the management of dyslipidaemias, 2016, pp.37, 2999~3058
- Athyros VG, "Atorvastatin : safety and tolerability", Expert Opin Drug Saf, 9, pp.667~674 (2010)